ONCOTARGET: THE JOURNAL YOU TRUST IN ALL ASPECTS OF ONCOLOGY

Oncotarget is a free- access journal that publishes papers on a weekly basis. The published articles constitute of a variety of disciplines that range from oncology, pharmacology, neuroscience, cardiology to Endocrinology. Since its inception, Oncotarget has been forefront in providing insight to many of its readers. The papers that are published are well- researched by experts from their various disciplines. Also, they publish new scientific breakthroughs to help other researchers succeed in their endeavors. Visit Oncotarget’s profile page at Facebook.

The Oncotarget journal has become a favorite magazine, and this can be attributed to various reasons. First and foremost, the editors in chief of the journal are prolific scientists. The editors in chief of the magazine are two well- known experts; Mikhail Blagosklonny and Andrei V. Gudkov. These experts serve as the senior editors of the paper. Through their leadership, Oncotarget has published articles on the scientific breakthroughs and research on oncology and other medicine-related disciplines. Currently, this journal has published more than 250 papers in various disciplines.

Secondly, the free- access option of the journal has been fundamental in capturing many of its readers. This open access feature lacks in many magazines, especially journals that publish papers on oncology. Due to this, many scientist and researchers have benefitted from the research findings posted on this journal.

Lastly, the editors and expert who wrote the journal are experienced and well versed in their various disciplines. Each week the journal publishes papers about a new concept or research. The journals captivate the readers and provide them with new information on Oncology, Cell biology, and neuroscience.

Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget

More recently, Oncotarget published a paper on the nutrition. The article was written by, Anke Schloesser, Gerald Rimbach, and Patricia Huebbe. The article provided insight on the difference between calorie restriction and dietary restrictions. Furthermore, the report illustrated the impact that both calorie restriction and dietary restriction have on human lifespan.

The research findings of this paper were published after a long and vigorous testing of the above factors on mice.

The Notable Diffenence Eric Lefkofsky Is Acheiving Regarding Breast Cancer

The cancer fighting group called Tempus is trying to give more help to the doctors at the University of Chicago. Eric Lefkofsky, the founder of Tempus wants breast cancer patients to have better treatments available. For this purpose Tempus and the University of Chicago have achieved a partnership.One of the most common types of cancer is breast cancer yet there is not much data accessible on the people who have fought the disease. Doctors are forced to make decisions regarding treatment without information that could aid in the process.

Genomic sequencing and machine learning are used by Tempus to help doctors make more personal decisions in the treatment of their patients. This process was started in 2015 and just recently came to light.Tempus has been setting up numerous partnerships. They work with the University of Michigan, the Robert H. Lurie Comprehensive Cancer Center, Penn Medicine, the Mayo Clinic and Rush University Medical Center in the pursuit of data that can be used in the fight against cancer.

Eric Lefkofsky is one of the founders as well as the CEO of Tempus. He was also a partner in the founding of Lightbank. This is a venture fund specializing in disruptive technologies. Mr. Lefkofsky is well known as the Chairman and co-founder of Groupon, a highly successful e-commerce website.Mr. Lefkofsky started the Lefkofsky Family Foundation in 2006 along with his wife Liz. This private charitable foundation works to advance initiatives that positively affect the lives of the people in the communities they serve. Mr. Lefkofsky is a Trustee at many worthwhile organizations. These include World Business Chicago, The Museum of Science and Industry, The Art Institute of Chicago and the Lurie Children’s Hospital of Chicago.Mr. Lefkofsky is on the board for the Chicago’s Steppenwolf Theatre Company as well as supporting the University of Chicago. In addition he has written Accelerated Disruption. Mr. Lefkofsky attended the University of Michigan where he graduated then earned his Juris Doctor in Law school.

 

Eric Lefkofsky, Tempus, and a New Era of Cancer Research

Eric Lefkofsky, J.D., has always been an entrepreneur and a lover of technology. As the co-founder of several big-name companies like Groupon, Echo Global Logistics, and Mediaocean (to name just a few), he has a track record of pushing the limits of how society implements technology. His projects focus on using technology to increase efficiency, communication, and understanding.

With Tempus, he’s taking all that a step further. Tempus is a Chicago-based genetic sequencing company, co-founded by Lefkofsky, that wants to redefine how genomic data is used to fight cancer. Lefkofsky also serves as its CEO. Tempus’s labs don’t just collect molecular data; the company also provides a platform for that data to be analyzed in an unprecedented way. “We built a system to help physicians in clinic analyze incredible amounts of data and make real-time decisions to more effectively treat patients,” Lefkofsky said of Tempus. Tempus’s goal is to fight cancer by giving patients access to personalized treatment plans and by giving physicians the the tools that they need to analyze data effectively and share that data with others.

Now in 2017, Tempus is partnering specifically with University of Chicago Medicine to help with breast cancer research. Tempus will be sequencing and analyzing data from around 1,000 breast cancer patients. Even though breast cancer is one of the more common cancers treated by University of Chicago Medicine, professor of medicine and human genetics Dr. Olufunmilayo Olopade says that “there is relatively little accessible data on the millions of patients who have battled the disease.” Tempus wants to change that.Eric Lefkofsky and the other brilliant minds at Tempus believe that if they can help physicians and researchers uncover patterns about how breast cancer patients respond to treatment, they can help create personalized plans that are more effective for treating future patients.Tempus’s partnership with University of Chicago Medicine marks the beginning of a new era of cancer research, one which Lefkofsky hopes will make a difference in the way physicians treat breast cancer.